Trials / Completed
CompletedNCT00127647
An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)
MK0476 Phase III Double-Blind Comparative Study - Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,375 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 15 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to evaluate the efficacy and safety of an investigational drug in adult patients with allergic rhinitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | montelukast sodium | montelukast sodium; 5 mg, 10 mg QD 2-weeks. |
| DRUG | Comparator: pranlukast | Pranlukast 225 mg BID 2-weeks. |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2005-04-01
- Completion
- 2005-04-01
- First posted
- 2005-08-08
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00127647. Inclusion in this directory is not an endorsement.